A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy

Trial Profile

A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs T cell replacement therapy TH 9402 (Primary) ; Cyclophosphamide
  • Indications Graft-versus-host disease; Haematological malignancies; Leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HATCY
  • Sponsors Kiadis Pharma
  • Most Recent Events

    • 04 Dec 2017 According to a Kiadis Pharma media release, the first patient has been enrolled in this trial.
    • 19 Sep 2017 According to a company media release, Kiadis Pharma has received regulatory approval in various countries to start dosing patients this trial that will be performed across Europe and North America.
    • 19 Jul 2017 Planned initiation date changed from 1 May 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top